Natriuresis With Acetazolamide or SGLT2 Inhibitors Added to Intravenous Loop Diuretics in Decompensated Heart Failure (GLIDE-DHF)
Natriuresis in Decompensated Heart Failure Patients Treated With Intravenous Loop Diuretics Alone or in Combination With an SGLT2 Inhibitor or Acetazolamide: a Single-Center, Prospective, Open-Label, Non-Randomized, Controlled Interventional Study (GLiflozin or AcetazolamIDE on Top of Loop Diuretics in Decompensated Heart Failure)
The GLIDE-DHF study compares the natriuretic effect of adding acetazolamide or a sodium-glucose co-transporter 2 inhibitor (SGLT2i) to intravenous loop diuretics, versus intravenous loop diuretics alone, in patients admitted to the emergency department with acute decompensated heart failure. Natriuresis is assessed by spot urinary sodium concentration measured 6 hours after the first study treatment. The study also evaluates changes in urinary and serum electrolytes, kidney function, blood pressure, clinical congestion and safety during the first 3 days of treatment.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 4단계
연락처 및 위치
연구 장소
-
-
Porto District
-
Porto, Porto District, 포르투갈, 4200-319
- Unidade Local de Saúde São João
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥18 years
- Admission to the emergency department with a primary diagnosis of decompensated heart failure
- Inclusion within the first 24 hours after emergency department admission
- In patients who received intravenous loop diuretics before inclusion, baseline urine sample collected at least 6 hours after the last loop diuretic dose
- Written informed consent
Exclusion Criteria:
- Hemodynamic instability (systolic blood pressure <90 mmHg and/or serum lactate >2 mmol/L)
- Decompensated heart failure in the setting of an acute coronary syndrome
- Chronic maintenance therapy with an SGLT2 inhibitor or acetazolamide before the current episode
- Baseline estimated glomerular filtration rate (outside the acute episode) <20 mL/min/1.73 m²
- Renal replacement therapy
- Metabolic or respiratory acidosis (arterial pH <7.35)
- Sodium bicarbonate administration before inclusion
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Loop diuretic alone (LD)
Intravenous furosemide. Initial dose: twice the oral outpatient dose (maximum 160 mg IV), or 40 mg IV in patients not on chronic loop diuretics. Subsequent dose adjustments at the attending physician's discretion. |
Intravenous furosemide; initial dose twice the oral outpatient dose (max 160 mg) or 40 mg if loop diuretic-naïve; subsequent adjustments per attending physician. |
|
실험적: Loop diuretic + SGLT2 inhibitor (LD+SGLT2i)
Intravenous furosemide (as in the LD arm) plus oral dapagliflozin 10 mg or empagliflozin 10 mg once daily, started on day 1. SGLT2i may be continued after day 3. |
Intravenous furosemide; initial dose twice the oral outpatient dose (max 160 mg) or 40 mg if loop diuretic-naïve; subsequent adjustments per attending physician. Oral dapagliflozin 10 mg once daily. Oral empagliflozin 10 mg once daily. |
|
실험적: Loop diuretic + acetazolamide (LD+A)
Intravenous furosemide (as in the LD arm) plus intravenous acetazolamide 500 mg once daily for a maximum of 3 days (maximum 3 administrations). |
Intravenous furosemide; initial dose twice the oral outpatient dose (max 160 mg) or 40 mg if loop diuretic-naïve; subsequent adjustments per attending physician. Intravenous acetazolamide 500 mg once daily for up to 3 days. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in spot urinary sodium concentration at 6 hours
기간: Baseline and 6 hours after the first study treatment administration (day 1)
|
Change in spot urinary sodium concentration (mmol/L) from baseline to 6 hours after the first study treatment administration. The main comparison is LD+A versus LD alone; the comparison of LD+SGLT2i versus LD alone is secondary. |
Baseline and 6 hours after the first study treatment administration (day 1)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in spot urinary sodium concentration at day 3
기간: Baseline and 6 hours after the third study treatment administration (day 3)
|
Change in spot urinary sodium (mmol/L) from baseline to 6 hours after the third study treatment administration. |
Baseline and 6 hours after the third study treatment administration (day 3)
|
|
Proportion of patients with spot urinary sodium >70 mmol/L
기간: 6 hours after first administration (day 1)
|
Percentage of patients achieving spot urinary sodium >70 mmol/L 6 hours after the first study treatment administration. |
6 hours after first administration (day 1)
|
|
Change in spot urinary potassium
기간: Baseline, 6 hours after first administration (day 1) and 6 hours after third administration (day 3)
|
Change in spot urinary potassium (mmol/L) from baseline. |
Baseline, 6 hours after first administration (day 1) and 6 hours after third administration (day 3)
|
|
Change in spot urinary magnesium
기간: Baseline, 6 hours after first administration (day 1) and 6 hours after third administration (day 3)
|
Change in spot urinary magnesium from baseline. |
Baseline, 6 hours after first administration (day 1) and 6 hours after third administration (day 3)
|
|
Change in spot urinary phosphate
기간: Baseline, 6 hours after first administration (day 1) and 6 hours after third administration (day 3)
|
Change in spot urinary phosphate from baseline. |
Baseline, 6 hours after first administration (day 1) and 6 hours after third administration (day 3)
|
|
Change in estimated glomerular filtration rate (eGFR)
기간: Baseline and day 3
|
Change in eGFR (mL/min/1.73 m²) from baseline. |
Baseline and day 3
|
|
Change in hemoglobin
기간: Baseline and day 3
|
Change in hemoglobin (g/dL) from baseline. |
Baseline and day 3
|
|
Change in hematocrit
기간: Baseline and day 3
|
Change in hematocrit (%) from baseline. |
Baseline and day 3
|
|
Change in serum urea
기간: Baseline and day 3
|
Change in serum urea (mg/dL) from baseline. |
Baseline and day 3
|
|
Change in serum sodium
기간: Baseline and day 3
|
Change in serum sodium (mmol/L) from baseline. |
Baseline and day 3
|
|
Change in serum potassium
기간: Baseline and day 3
|
Change in serum potassium (mmol/L) from baseline. |
Baseline and day 3
|
|
Change in serum chloride
기간: Baseline and day 3
|
Change in serum chloride (mmol/L) from baseline. |
Baseline and day 3
|
|
Change in systolic blood pressure
기간: Baseline, day 2 and day 3
|
Change in systolic blood pressure (mmHg) from baseline. |
Baseline, day 2 and day 3
|
|
Change in diastolic blood pressure
기간: Baseline, day 2 and day 3
|
Change in diastolic blood pressure (mmHg) from baseline. |
Baseline, day 2 and day 3
|
|
Change in clinical congestion score
기간: Baseline, day 2 and day 3
|
Change in the clinical congestion score from baseline. The clinical congestion score is a composite score based on three items (orthopnea, peripheral edema and jugular venous pressure elevation), each graded from 0 to 3, with a total score ranging from 0 (no congestion) to 9 (maximum congestion). Higher scores indicate a worse outcome (more congestion). |
Baseline, day 2 and day 3
|
|
Proportion of patients with clinical decongestion
기간: Day 3
|
Percentage of patients achieving clinical decongestion, defined as a clinical congestion score ≤2 points. The clinical congestion score is a composite score based on orthopnea, peripheral edema and jugular venous pressure elevation, each graded from 0 to 3 (total score 0-9; higher scores indicate more congestion). |
Day 3
|
|
Cumulative intravenous loop diuretic dose
기간: Up to day 3
|
Cumulative intravenous furosemide dose (mg) administered up to day 3. |
Up to day 3
|
|
Incidence of hypokalemia
기간: Baseline to day 3
|
Percentage of patients with serum potassium <3.5 mmol/L. |
Baseline to day 3
|
|
Incidence of severe hypokalemia
기간: Baseline to day 3
|
Percentage of patients with serum potassium <3.0 mmol/L. |
Baseline to day 3
|
|
Incidence of hyponatremia
기간: Baseline to day 3
|
Percentage of patients with serum sodium <135 mmol/L. |
Baseline to day 3
|
|
Incidence of hypotension
기간: Baseline to day 3
|
Percentage of patients with systolic blood pressure <90 mmHg. |
Baseline to day 3
|
|
Incidence of stage 2 acute kidney injury
기간: Baseline to day 3
|
Percentage of patients with stage 2 acute kidney injury according to the Kidney Disease: Improving Global Outcomes (KDIGO) staging criteria, defined as at least doubling of serum creatinine from baseline. KDIGO stages range from 1 to 3, with higher stages indicating more severe kidney injury (worse outcome). |
Baseline to day 3
|
|
Incidence of ≥50% increase in serum creatinine
기간: Baseline to day 3
|
Percentage of patients with ≥50% increase in serum creatinine from baseline. |
Baseline to day 3
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Length of hospital stay
기간: From emergency department admission until hospital discharge, assessed up to 90 days
|
Duration of index hospitalization (days). |
From emergency department admission until hospital discharge, assessed up to 90 days
|
|
In-hospital mortality
기간: From emergency department admission until hospital discharge, assessed up to 90 days
|
Death from any cause during index hospitalization. |
From emergency department admission until hospital discharge, assessed up to 90 days
|
|
All-cause mortality
기간: From study inclusion until death from any cause, assessed up to 90 days
|
Time to death from any cause. |
From study inclusion until death from any cause, assessed up to 90 days
|
|
Cardiovascular mortality
기간: From study inclusion until cardiovascular death, assessed up to 90 days
|
Time to cardiovascular death. |
From study inclusion until cardiovascular death, assessed up to 90 days
|
|
All-cause rehospitalization
기간: From hospital discharge until first rehospitalization for any cause, assessed up to 90 days after study inclusion
|
Time to first rehospitalization for any cause. |
From hospital discharge until first rehospitalization for any cause, assessed up to 90 days after study inclusion
|
|
Heart failure rehospitalization
기간: From hospital discharge until first rehospitalization for heart failure, assessed up to 90 days after study inclusion
|
Time to first rehospitalization for heart failure. |
From hospital discharge until first rehospitalization for heart failure, assessed up to 90 days after study inclusion
|
|
Composite of all-cause mortality or all-cause rehospitalization
기간: From study inclusion until the first occurrence of any component event, assessed up to 90 days
|
Time to first occurrence of all-cause death or all-cause rehospitalization. |
From study inclusion until the first occurrence of any component event, assessed up to 90 days
|
|
Composite of cardiovascular mortality or heart failure rehospitalization
기간: From study inclusion until the first occurrence of any component event, assessed up to 90 days
|
Time to first occurrence of cardiovascular death or heart failure rehospitalization. |
From study inclusion until the first occurrence of any component event, assessed up to 90 days
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Pedro M. Marques, MD, Unidade Local de Saúde São João, Oporto
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- GLIDE-DHF
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .